系统的配方优化,以提高对腺相关病毒 (AAV2) 载体的缓冲区交换恢复和存储稳定性
Braulio Carrillo Sanchez1, Raquel Fernández-García2, Spyridon Gerontas3
1Department of Biochemical Engineering, University College London, London WC1E 6BT, United Kingdom.
International journal of pharmaceutics
|October 28, 2025
概括
这项研究开发了一种针对腺相关病毒 (AAV) 载体的优化配方,提高了稳定性和保质期. 新配方提高了AAV的制造能力,并减少了对更好的基因疗法应用的聚合.
科学领域:
- 生物技术是生物技术.
- 基因治疗 基因治疗
- 制药科学 制药科学
背景情况:
- 重组腺相关病毒 (AAV) 载体是基因治疗的关键,但需要高度,冒着聚合和免疫反应的风险.
- 目前的AAV配方开发受到少数辅助剂和狭窄的度范围的限制.
研究的目的:
- 通过调查众多辅助剂和度来扩大AAV2配方工具箱.
- 为提高稳定性和可制造性,开发一个系统的框架来选,精制和优化AAV配方.
主要方法:
- 采用了系统的实验设计 (DOE) 方法,涉及三个实验步骤.
- 使用差异扫描度 (DSF) 评估辅助剂的作用,以测量热稳定性和大小排除高性能液体染色学 (SEC-HPLC) 以超过/透过 (UF/DF) 恢复.
主要成果:
- 开发了一种优化配方 (OptiDOE),实现化温度 (Tm) >70°C和UF/DF后恢复率>90%.
- 在40°C时,OptiDOE表现出极好的稳定性,在14天后保持了60%以上的传染性和87%以上的病毒颗粒度.
结论:
- 建立了一种方法方法,用于探索广泛的辅助剂和度,以提高AAV产品的制造性和保质期.
- 开发的OptiDOE配方为提高未来基于AAV的基因疗法的稳定性和有效性提供了一个有希望的解决方案.
相关概念视频
Rational Dosage Regimen: Maintenance Dose and Loading Dose
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...
Bioavailability Enhancement: Drug Permeability Enhancement
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...


